1. Home
  2. APLM vs GRNQ Comparison

APLM vs GRNQ Comparison

Compare APLM & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • GRNQ
  • Stock Information
  • Founded
  • APLM 2016
  • GRNQ 2013
  • Country
  • APLM United States
  • GRNQ Malaysia
  • Employees
  • APLM N/A
  • GRNQ N/A
  • Industry
  • APLM Blank Checks
  • GRNQ EDP Services
  • Sector
  • APLM Finance
  • GRNQ Technology
  • Exchange
  • APLM Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • APLM 7.7M
  • GRNQ 7.0M
  • IPO Year
  • APLM N/A
  • GRNQ 2018
  • Fundamental
  • Price
  • APLM $6.16
  • GRNQ $0.89
  • Analyst Decision
  • APLM Strong Buy
  • GRNQ
  • Analyst Count
  • APLM 2
  • GRNQ 0
  • Target Price
  • APLM $425.00
  • GRNQ N/A
  • AVG Volume (30 Days)
  • APLM 42.6K
  • GRNQ 14.3K
  • Earning Date
  • APLM 04-15-2025
  • GRNQ 05-12-2025
  • Dividend Yield
  • APLM N/A
  • GRNQ N/A
  • EPS Growth
  • APLM N/A
  • GRNQ N/A
  • EPS
  • APLM N/A
  • GRNQ N/A
  • Revenue
  • APLM $2,101,000.00
  • GRNQ $2,727,344.00
  • Revenue This Year
  • APLM N/A
  • GRNQ N/A
  • Revenue Next Year
  • APLM N/A
  • GRNQ N/A
  • P/E Ratio
  • APLM N/A
  • GRNQ N/A
  • Revenue Growth
  • APLM 70.54
  • GRNQ N/A
  • 52 Week Low
  • APLM $6.20
  • GRNQ $0.80
  • 52 Week High
  • APLM $63.00
  • GRNQ $2.24
  • Technical
  • Relative Strength Index (RSI)
  • APLM 42.37
  • GRNQ 45.72
  • Support Level
  • APLM $6.50
  • GRNQ $0.89
  • Resistance Level
  • APLM $8.00
  • GRNQ $0.95
  • Average True Range (ATR)
  • APLM 1.36
  • GRNQ 0.05
  • MACD
  • APLM -0.22
  • GRNQ 0.01
  • Stochastic Oscillator
  • APLM 5.93
  • GRNQ 25.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management, cross-border listing advisory services, and transaction services. It also operates a venture capital business. Its segments include Service business engaged in the provision of corporate advisory and business solution services; and Real estate business engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia.

Share on Social Networks: